Ali Nor Huda

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab (ALI) and evolocumab (EVO) have previously been evaluated through controlled clinical trials with selective patient groups. Post-commercially, in patients with heterozygous familial hypercholesterolemia (HeFH) and/or cardiovascular disease (CVD)(More)
Maternal complete atrioventricular block undergoing emergent operative procedure under general anaesthesia should always be managed with intraoperative temporary pacing. A 26-year-old gravida 2 parity 1, Indonesian migrant to Malaysia presented for her routine antenatal visit at 36 weeks of pregnancy. Ultra-sound examination revealed intrauterine growth(More)
  • 1